Getting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers
|
|
- Rhoda Walker
- 5 years ago
- Views:
Transcription
1 Getting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers Disclosures None Cindy L. O Bryant, PharmD, BCOP, FCCP, FHOPA Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe the current use of chemotherapy and radiation in the treatment of esophagogastric cancers Interpret the use of targeted therapies and immunotherapy in the management of esophagogastric cancers Evaluate supportive care and survivorship interventions for patients with esophagogastric cancers Incidence of Esophagogastric Cancers Esophageal & Esophagogastric Junction (EGJ) Cancers US estimations for 2018 New cases 17,290 Deaths 15,850 More common Men > women > older age, heavy alcohol use, tobacco use Median age of diagnosis 68-years old Median 5-year survival 19.2% US estimations for 2018 New cases 26,240 Deaths 10,800 More common Men > women > in other races and ethnicities that non- Hispanic whites Median age of diagnosis 68-years old Median 5-year survival 31% SEER Anatomy and Pathology Esophageal & EGJ Cancers Squamous cell (<30%) Commonly found in the upper and middle part of the esophagus Adenocarcinoma Most often found in the lower third of the esophagus Anatomy and Pathology Adenocarcinoma Diffuse Less differentiated Occurs in proximal stomach Intestinal More differentiated Occurs in distal stomach Rice TW et al. J Thor Oncol Page MR and Patel S. AMJC: Evidenced-Based Oncology June
2 Risk Factors Esophageal & EGJ Cancers Squamous cell (<30%) Smoking and alcohol Hereditary syndromes Adenocarcinoma Obesity/ BMI GERD Barrett s esophagus Adenocarcinoma Diet High salt intake and salt-preserved food High nitrate consumption Smoking H. Pylori infection Genetic syndromes Clinical Presentation Esophageal & EGJ Cancers Dysphagia Weight loss Odynophagia Anemia Hoarseness Aspiration pneumonia Early stage Stomach discomfort Bloated feeling after eating Nausea Loss of appetite Heartburn Advanced stage Blood in stool Vomiting Weight loss Stomach pain Jaundice Ascites Surgical Intervention Esophageal & EGJ Cancers Medically fit for surgery Stage 0-I Endoscopic therapies (preferred) Endoscopic resection + ablation Ablation Esophagectomy Stage II-III Esophagectomy (low risk disease) Non-surgical candidate Stage 0-I Endoscopic resection + ablation Ablation Medically fit for surgery Stage 0-I Endoscopic resection Gastrectomy National Comprehensive Cancer Network (NCCN) Esophageal and Esophagogastric Cancers v2.2018; NCCN Gastric Cancer v Stage Primary Treatment Option Esophageal & EGJ Esophageal & EGJ Gastric Squamous cell Adenocarcinoma Adenocarcinoma Medically fit II-III Preoperative chemoradiation Preoperative chemoradiation Perioperative (non-cervical) (category 1) chemotherapy (category 1) Definitive chemoradiation Definitive chemoradiation Preoperative (only for patient who declines (only for patient who declines chemoradiation surgery; recommended for surgery) cervical) Perioperative chemotherapy (thoracic) Preoperative chemotherapy (thoracic) IVa Definitive chemoradiation Definitive chemoradiation Perioperative Chemotherapy (invasion to Chemotherapy (invasion to chemotherapy (category 1) trachea, great vessels or trachea, great vessels or Preoperative heart) heart) chemoradiation Non-surgical II-IVa Definitive chemoradiation Definitive chemoradiation Chemoradiation (able to tolerate treatment) (able to tolerate treatment) Chemotherapy Palliative RT or best Palliative RT or best Palliative management supportive care (unable to supportive care (unable to tolerate treatment) tolerate treatment) Preoperative and perioperative chemotherapy Regimen Overall survival (OS) 5-year OS Pathological Complete Regression Preoperative (Adenocarcinomas of the thoracic esophagus & EGJ only) OEO2 1, months vs. 23% vs. 17.1% _ Cisplatin + 5-FU vs. surgery 13.3 months OEO months vs. 42% vs. 39% _ ECX vs. Cisplatin + 5-FU 23.4 months (3-year OS) Perioperative (Esophageal, EGJ and Gastric Cancers) MAGIC 4 NR 36.3% vs. 23% _ ECF vs. surgery AIO-FLOT 5 16% vs. 6% FLOT vs. ECF FNCLCC ACCORD 6 NR 38% vs. 24% _ Cisplatin + 5-FU vs. surgery Regimens Preoperative Chemotherapy 2 cycles Recommended regimen Cisplatin + 5-FU (Category 2B) Perioperative Chemotherapy 3 cycles pre- & post-operative Preferred regimens 5-FU + oxaliplatin (category 2A) 5-FU, leucovorin, oxaliplatin, docetaxel (FLOT) (category 1) Other recommended regimen Cisplatin + 5-FU (category 1) ECX - epirubicin, capecitabine, oxaliplatin; ECF epirubicin, cisplatin, 5-FU; FLOT- 5-FU, leucovorin, oxaliplatin, docetaxel 1. Medical Research Council Oesophageal Cancer Working Group. Lancet 2002.; 2. Allum WH et al. J Clin Oncol 2009.; 3. Anderson D et al. J Clin Oncol 2015.; 4 Cunningham D et al. N Eng J Med 2006.; 5. Al-Batran SE et al. Lancet Oncol 2016.; 6. Ychou M et al. J Clin Oncol
3 Preoperative chemoradiation CROSS trial Randomized, Phase III trial in resectable esophageal or EGJ cancer N = 368 Surgery alone vs. carboplatin + paclitaxel + concurrent radiation followed by surgery Primary endpoint: Overall survival (OS) Results Median OS 49.4 months in the chemoradiotherapy surgery group vs months in the surgery group (HR 0.657; 95% CI to 0.871; P=0.003) Complete resection (R0) achieved in 92% of patients in the chemoradiotherapy surgery group vs. 69% in the surgery group (P<0.001) Most common side effects in the chemoradiotherapy-surgery group were leukopenia, neutropenia, anorexia and fatigue Preoperative Chemoradiation Preferred regimens Carboplatin + paclitaxel (category 1) 5-FU + oxaliplatin* (category 1) Other recommended regimens Cisplatin + 5-FU (category 1) Paclitaxel + fluoropyrimidine (5-FU or capecitabine) (category 2B) Irinotecan + cisplatin (category 2B) (esophageal & EGJ cancers only) *Infusional 5-FU can be replaced with capecitabine Van Hagen P et al. N Engl J Med Postoperative management Has not received preoperative chemoradiation or chemotherapy R0 resection R1 resection R2 resection Surveillance Chemoradiation (5-FU-based)* Chemoradiation (5-FU-based) Chemoradiation (5-FU-based) Palliative management *Esophageal, EGJ and gastric adenocarcinoma only Postoperative chemoradiation SWOG9008/INT-0116 Randomized, Phase III trial in resectable EGJ or stomach cancer N = 566 Surgery alone vs. surgery + postoperative chemoradiation with bolus 5-FU and leucovorin before, during, and after radiotherapy Primary endpoint: Overall survival (OS) Results Median OS 36 months in the postoperative chemoradiation arm vs. 27 months in the surgery arm (HR 1.35; 95% CI 1.09 to 1.66; P=0.005) 3-year OS 50% months in the postoperative chemoradiation arm vs. 41% in the surgery arm Dosing associated with increased rates of grade 3-4 toxicities Regimen is not recommended by NCCN Infusional 5-FU and leucovorin or capecitabine recommended MacDonald JS et al. N Engl J Med Postoperative management Has received preoperative chemoradiation or chemotherapy R0 resection R1 resection R2 resection Surveillance Chemotherapy (if receive preoperatively) Chemoradiation (5-FU-based)* Surveillance Chemoradiation (5-FU-based) Chemotherapy (if receive preoperatively) # Consider re-resection^ Surveillance Chemoradiation (5-FU-based)^ Palliative management Esophageal & EGJ Cancers Definitive chemoradiation RTOG ,2 Chemoradiation with Cisplatin + 5-FU vs. radiation alone N = 121 Primary endpoint: OS Results Median OS 14 months in chemoradiation arm vs. 9 months in radiation alone arm 5-year OS 27% in chemoradiation arm vs. 0% in radiation alone arm PRODIGE5/ACCORD17 3 Chemoradiation + FOLFOX vs. Cisplatin + 5-FU N = 134 Primary endpoint: Progression-free survival (PFS) Results Median PFS 9.7 months in FOLFOX arm vs. 9.4 months in 5-FU + cisplatin arm FOLFOX a more convenient option *Esophageal & EGJ adenocarcinoma only; #Gastric cancer only; ^Esophageal, EGJ and gastric adenocarcinoma 1. Herskovic A et al. N Eng J Med. 1992; 2. Copper JS et al. JAMA. 1999; 3. Conroy T et al Lancet Oncol
4 Definitive Chemoradiation Preferred regimens Cisplatin + 5-FU (category 1) 5-FU + oxaliplatin* (category 1) Paclitaxel + carboplatin (category 2A) Other recommended regimens Cisplatin + docetaxel or paclitaxel (category 2A) Irinotecan + cisplatin (category 2B) Paclitaxel + fluoropyrimidine (5-FU or capecitabine) (category 2B) *Infusional 5-FU can be replaced with capecitabine Supportive Care Issues in Early Stage Cancer Smoking cessation Nutritional support Adequate hydration and caloric intake Feeding tubes Jejunostomy > gastrostomy Anti-emetics appropriate for treatment regimen ph altering medications Side effect management Mucositis Diarrhea Neuropathy Pain management NCCN Esophageal and Esophagogastric Junction Cancer v Survivorship Care General Routine surveillance Annual history and physical Maintain healthy lifestyle Healthy body weight Physical activity Healthy diet Limit alcohol consumption Smoking cessation Immunizations Cancer screening Survivorship Care Management of long-term sequelae Malnutrition/Malabsorption Weight loss Vitamin deficiencies Vit B12, Vit D, Calcium, Iron Delayed gastric emptying Dumping syndrome Diarrhea Nausea Indigestion ph altering medications Blood pressure and blood glucose issues (esophageal cancers) Chemotherapy-induced neuropathy Radiation-induced cardiotoxicity (esophageal cancers) Fatigue Bone health Unresectable locally advanced, Locally recurrent or Metastatic disease Karnofsky PS > 60% or ECOG PS < 2 Karnofsky PS < 60% or ECOG PS > 3 Systemic therapy and/or Palliative/Best supportive care Palliative/Best supportive care First-line Chemotherapy Preferred Regimen CF 1 (category 1) Cisplatin mg/m 2 IV D1 5-FU mg/m 2 CIV D1-4 every 28 days XP 2 (category 1) Cisplatin 80 mg/m 2 IV D1 Capecitabine 1000 mg/m 2 PO BID on D1-14 every 21 days FOLFOX 3 Oxaliplatin 85 mg/m 2 IV D1 Leucovorin 400 mg/m 2 IV D1 5-FU 400 mg/m 2 IV D1 5-FU 1200 mg/m 2 CIV D1&2 every 14 days CapeOx 4 Oxaliplatin 130 mg/m 2 IV D1 Capecitabine 1000 mg/m 2 PO BID on D1-14 every 21 days * TTP - time to progression Response Rate TTP/PFS OS 35% n/a 8.3 months 41% 5.6 months 10.5 months 41% 5.6 months 10.7 months 44% 12.4 months 13.3 months 1. Bleiberg H et al. Eur J Cancer Al Batran SE et al. J Clin Oncol Kang YK et al. Ann Oncol Kim GM et al. Eur J Cancer
5 Event First-line Chemotherapy Regimen Other Recommended DCF 1 Docetaxel 75 mg/m 2 D1 Cisplatin 75 mg/m2 D1 5-FU 750 mg/m 2 CIV D1-5 every 21 days ECF 2 Epirubicin 50 mg/m 2 D1 Cisplatin 60 mg/m 2 D1 5-FU 200 mg/m 2 /d CIV D1 21 every 21 days Carbo/paclitaxel 3 Carboplatin AUC 5 IV D1 Paclitaxel 200 mg/m 2 IV D1 every 21 days FOLFIRI 4 Irinotecan 180 mg/m 2 Lecovorin 400 mg/m 2 5-FU 400 mg/m 2 bolus followed by 2400 mg/m 2 CIV every 2 weeks Response Rate TTP/PFS OS 37% 5.6 months 9.2 months 42% 7.0 months 9.4 months 33% 4.9 months 7.5 months 39% 5.3 months 9.5 months Biomarkers Human epidermal growth factor receptor (HER2) Esophagogastric cancers Positivity varies from 2-45% Adenocarcinoma > Squamous Gastric cancer Positivity varies from12-23% Intestinal > Diffuse Prognostic significance unclear Testing recommended in metastatic disease * TTP - time to progression 1. Van Cutsem E et al. J Clin Oncol Ross P et al. J Clin Oncol Gadgeel SM et al. Am J Clin Oncol Guimbaud R et al. J Clin Oncol ToGA Trial HER2-positive advanced GC (N = 594) Stratified Advanced vs metastatic GC vs GEJ cancer Measurable vs non-measurable ECOG PS 0 1 vs 2 Capecitabine vs 5FU 5FU or Capecitabine* a + cisplatin (n = 290) 5FU or Capecitabine a + cisplatin + trastuzumab (n = 294) a Chosen at investigator s discretion. Phase III, randomized, open-label, international, multi-center study 3807 screened ; 810 (22.1%) HER2-positive Primary end point: OS ToGA Primary Endpoint: Overall Survival Time (months) FC FC + T FC + T n = 294 FC n = 290 Events, no Median OS, mos HR = 0.74 (95% CI, ) P=0.046 Benefit limited to patients with IHC 3+ or IHC 2+ and FISH positivity OS 16 months FC + T vs months FC Bang YJ et al. Lancet FC - 5FU or capecitabine + cisplatin; T - trastuzumab. Bang YJ et al. Lancet First-line Treatment Targeted Therapy HER2-positive disease Trastuzumab should be added to first-line chemotherapy for HER2 overexpressing metastatic adenocarcinomas It is not recommended for use with anthracyclines Biomarkers Deficient mismatch repair/microsatellite instability-high (dmmr/msi-h) Site-agnostic indication Testing recommended in metastatic disease Programmed death-ligand 1 (PD-L1) Testing recommended in metastatic disease Pembrolizumab Recurrent, locally advanced, metastatic EGJ cancer Gastric cancer Tumors with CPS > 1 Third or subsequent-line of treatment Epstein-Bar Virsus (EBV) Gastric cancer Testing not recommended at this time 5
6 Overall survival probability -currents-blog/2017/esophageal-genomic-subtypes New Molecular Classification of Gastroesophageal Cancers REGARD Trial Previously treated gastric or GEJ adenocarcinoma N = 355 Stratification factors: Region Weight loss ( 10% vs <10% over 3 months) Location of primary tumor (gastric vs GEJ) R A N D O M I Z E 2:1 Ramucirumab 8 mg/kg q2wk + BSC (n = 238) Placebo q2wk + BSC (n = 117) Multicenter, randomized, double-blind, placebo-controlled, phase III trial Primary endpoint: OS ESCC esophageal squamous cell; CIN - chromosomal instability; GS = genomically stable Fuchs CS et al. Lancet REGARD Trial Primary Endpoint Ramucirumab Placebo Patients/events 238 / / 99 Median OS, months (95% CI) 5.2 ( ) 3.8 ( ) 6-month OS 42% 32% 12-month OS 18% 11% HR = (95% CI, ) Log rank (stratified) P= REGARD Trial Adverse events Ramucirumab (n = 236) Placebo (n = 115) Any Grade Grade 3 Any Grade Grade 3 (%) (%) (%) (%) Hypertension Bleeding/Hemorrhage Arteriothromboembolic Venous thromboembolic Proteinuria 3 <1 <1 <1 GI perforation <1 <1 <1 <1 Fistula (GI and non-gi) <1 <1 <1 <1 Infusion-related reaction < Cardiac failure < Fuchs CS et al. Lancet Fuchs CS et al. Lancet RAINBOW Trial N=665 Metastatic or locally advanced unresectable gastric or GEJ adenocarcinoma Progression after first-line platinum/fluoropyrimidinebased chemotherapy R A N D O M I Z E Ramucirumab 8 mg/kg on days 1 and 15 + paclitaxel 80 mg/m 2 on days 1, 8, and 15 of 28-day cycle n = 330 Placebo on days 1 and 15 + paclitaxel 80 mg/m 2 on days 1, 8, and 15 n = 335 Randomized, placebo-controlled, double-blind phase III trial Stratification factors Geographic region Measurable vs non-measurable disease Time to progression on first-line therapy (<6 mos vs 6 mos Primary endpoint: OS RAINBOW Trial Overall Survival No. at risk Ramucirumab + Paclitaxel Median (mos) (95% CI) 9.63 ( ) Δ RAM mos + = 2.3 PTXmonth Months Placebo + Paclitaxel 7.36 ( ) 6-month OS 72% 57% 12-month OS 40% 30% PBO + PTX RAM - Ramucirumab; PTX - Paclitaxel; PBO - Placebo HR = (95% CI, ) Stratified log rank P= Wilke H et al. Lancet Oncol Wilke H et al. Lancet Oncol
7 RAINFALL Trial Randomized, Phase III, first-line study in patients with metastatic gastric or gastroesophageal junction adenocarcinoma N=21 HER2- Cisplatin + capecitabine or 5-FU + ramucirumab Primary endpoint: PFS Secondary endpoint: OS Median PFS 5.7 months vs. 5.4 months (HR 0.75, 95% CI , p=0.0024) Median OS months vs months NS Increase in ramucirumab-related adverse events Second-line or Subsequent Therapy Based on prior therapy and performance status Preferred regimens Ramucirumab + paclitaxel (category 1) Docetaxel (category 1) Paclitaxel (category 1) Irinotecan (category 1) 5-FU + irinotecan Pembrolizumab MSI-H or dmrr tumors Other recommended regimens Ramucirumab (category 1) Irinotecan + cisplatin Pembrolizumab Third-line or subsequent for PD-L1 positive adenocarcinoma Docetaxel + irinotecan Fuchs CS et al. J Clin Oncol. 2018;36(suppl 4): abstract 5. Checkpoint Immunotherapy Pembrolizumab Approved for second line or subsequent use in MSI-H or dmrr tumors KEYNOTE-016 Phase II with dmmr non-colorectal arm (at least two prior therapies) N=9 KEYNOTE-012 Recurrent or metastatic adenocarcinoma of stomach or GEJ ECOG PS 0 1 PD-L1 + tumor No systemic steroid therapy No autoimmune disease (active or history of) No active brain metastases Pembrolizumab 10 mg/kg Q2W Immune-related Median PFS Median OS Grade 3-4 Treatment Arm Overall Response (months) (months) Adverse Events Rate (ORR) Pembrolizumab 10mg/kg 71% 5.4 NR 41% IV Q 2 weeks Adverse events Pruritus, hypothyroidism, asymptomatic pancreatitis, anemia Phase 1b multicenter, open-label trial Only patients with PD-L1 staining in stroma or in 1% of tumor cells were eligible for enrollment 65 of 162 (40%) patients assessed for PD-L1 expression had PD-L1+ tumors Trial endpoints: Overall response rate and safety LE DT J et al. N Eng J Med Muro K et al. Lancet Oncol KEYNOTE-012 Response with Pembrolizumab Central Review Investigator Review n = 36 n = 39 ORR, % (95% CI) 22.2 ( ) 33.3 ( ) Best overall response, n (%) Complete response 0 0 Partial response 8 (22.2) 13 (33.3) Stable response 5 (13.9) 5 (12.8) Progressive disease 19 (52.8) 21 (53.8) No assessment 1 (2.8) Not determined 3 (8.3) KEYNOTE-012: Adverse events of interest Event, n (%) Grade 1 2 Grade 3-4 Any 7 (17.9) 2 (5.2) Hypothyroidism 4 (10.3) 1 (2.6) Hyperthyroidism 3 (7.7) 0 (0.0) Pneumonitis 1 (2.6) 1 (2.6) Colitis 1 (2.6) 0 (0.0) Hepatitis 1 (2.6) 0 (0.0) Thyroiditis 1 (2.6) 0 (0.0) Muro K et al. Lancet Oncol AE = adverse event. Muro K et al. Lancet Oncol
8 KEYNOTE-059 COHORT 1 PD-L1 + or PD-L1 Prior systemic therapies N = 180 Pembrolizumab 200 mg Q3W COHORT 2 PD-L1 + or PD-L1 No prior systemic therapy N = 40 Pembrolizumab 200 mg + cisplatin + 5-FU, all Q3W COHORT 3 PD-L1 + only No prior systemic therapy N=50 Pembrolizumab 200 mg Q3W Phase II trial Cohort 1 - advanced gastric or GEJ adenocarcinoma progressed on two or more lines of therapy A specimen is considered to have positive PD-L1 expression if combined positive score (CPS) 1% Primary endpoint: ORR Cohorts 2 and 3 enrollment is ongoing Muro K et al. J Clin Oncol. 2015;33(suppl 3): abstract 3. KEYNOTE-059 Cohort 1 ORR for all patients 11.6% Response PD-L1 Positive (n = 148) Median duration of response 16.3 months PD-L1+ vs. 6.9 months PD-L1- PD-L1 Negative (n = 109) % 95% CI % 95% CI ORR (CR + PR) CR PR DCR DCR = CR + PR + SD 2 months Fuchs CS et al. J Clin Oncol. 2017;35(suppl): abstract CheckMate-032 Nivolumab 3 mg/kg IV every 2 weeks R Metastatic or locally n = 59 advanced chemotherapy A refractory gastric, esophageal N or GEJ cancer D Nivolumab 1mg/mkg IV N=160 O Ipilimumab 3 mg/kg IV every 3 weeks M n = 49 ECOG 0 or 1 I HER2 + if received Z trastuzumab Nivolumab 3 mg/mkg IV E Ipilimumab 1 mg/kg IV every 3 weeks n = 52 Open-label, two-stage multicohort, phase I/II trial PD-L1 status assessed Primary endpoint: ORR CheckMate-032 Nivolumab 3 mg/kg Nivolumab 1 mg/kg Ipilimumab 3 mg/kg Nivolumab 3 mg/kg Ipilimumab 1 mg/kg ORR 12% (95% CI 5-23%) 24% (95% CI 13-39%) 8% (95% CI 2-19%) 12-month PFS 8% 17% 10% 12-month OS 39% 35% 24% Grade 3/4 17% 47% 27% adverse events Response observed regardless of PD-L1 status Adverse events Most common Fatigue, rash, pruritus, diarrhea, decrease appetite, increased AST/ALT Janjigian YY et al. J Clin Oncol Janjigian YY et al. J Clin Oncol Best Supportive Care Goal To prevent, reduce and relieve suffering Improve quality of life Common symptoms Dysphagia Alternate route for medications Obstruction Alternate route for medications Bleeding Anemia management ph altering medications Pain Nausea/vomiting Summary The treatment of esophagogastric cancer requires a multidisciplinary approach and pharmacists play an important part Preoperative chemoradiation has been shown to improve survival in locoregional esophagogastric cancer Increased molecular understanding of esophagogastric cancers has lead to the development of targeted and immunotherapy treatment options Appropriate monitoring and management of drug- and treatmentrelated toxicities are key for optimal patient outcomes Continued research in these cancers is necessary to provide better understanding of current and future therapeutic options 8
Chemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationCurrent standards of care in gastric cancer
Current standards of care in gastric cancer Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Outline Resectable gastric cancer: the role of neoadjuvant and adjuvant
More informationUpdated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)
Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationUpdates and best practices in the management of gastric cancer
Updates and best practices in the management of gastric cancer Olatunji B. Alese, MD Gastrointestinal Oncology, Winship Cancer Institute of Emory University July 28, 2017 1 Incidence 3rd leading cause
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationGastric: 16% 18% 27% Esophageal: 5% 10% 19%
2.5% of all cancers Median age 68 years Decline in gastric cancer incidence Increase in esophageal, GEJ, cardia adenocarcinoma OS improvement, 1975-77, 1984-86, 1999-2006 Gastric: 16% 18% 27% Esophageal:
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationSystemic treatment in early and advanced gastric cancer
Systemic treatment in early and advanced gastric cancer Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer n Surgical resection n Pathology assessment and estimation
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationPerioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran
Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center
More informationCHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationNew experimental targets for gastric cancer Andrés Cervantes
New experimental targets for gastric cancer Andrés Cervantes Professor of Medicine Outline Acquired capabilities of Cancer IGFR pathway PI3K-AKT-m-TOR pathway MET pathway FGFR pathway Check point inhibitors
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationCurrent Standard of Care of Gastric Cancer:
Current Standard of Care of Gastric Cancer: Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation of risk Treatment
More information(Neo-) adjuvant Treatment of Gastric Cancer. - The European View
(Neo-) adjuvant Treatment of Gastric Cancer - The European View Florian Lordick, MD Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) University of Leipzig, Germany My Conflict
More informationGastric cancer is the fourth
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Ramucirumab: A New Therapy for Advanced Gastric Cancer ANDREA LANDGRAF OHOLENDT, PharmD, BCOP, and JENNIFER L. ZADLO, PharmD, BCOP From The University
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationEsophageal and GEJ Cancers. Case Presentations
Esophageal and GEJ Cancers Case Presentations Locally Advanced GEJ Cancer (Case 1) A 55 year old man with longstanding GERD presents with increasing solid food dysphagia. EGD reveals a 3 cm mass in the
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationCurrent Standard of Care of Gastro- Esophageal Cancer
Current Standard of Care of Gastro- Esophageal Cancer Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation of risk
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationTumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla.
Tumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla. Santander Finantial disclosure Consultor: CELGENE Research fundings:
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationUpper Gastrointestinal Cancers in the Elderly. Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore
Upper Gastrointestinal Cancers in the Elderly Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore Gastric Cancer --High Global Burden Global Cancer Deaths % of all cancer (2008)
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationPCPA Advanced Trainee Program Upper GI Cancers. Dr N Singhal Medical Oncologist Royal Adelaide Hospital
Upper GI Cancers Dr N Singhal Medical Oncologist Royal Adelaide Hospital Localised disease PCPA Advanced Trainee Program 2018 Submucosal PCPA Advanced Trainee Program 2018 Work up EUS- 90% sensitivity
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationConcept to Practice: New Advances in the Treatment of GI Cancers
Concept to Practice: New Advances in the Treatment of GI Cancers 2016 Community Oncology Alliance Conference Orlando, FL Thomas George, MD, FACP Director, GI Oncology Program Director, Experimental Therapeutics
More informationUpdated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
Local Esophageal Cancer Summary Updated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationEsophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment
Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering Cancer Center Preop Therapy in Esophageal and
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationAdvances in gastric cancer: Biology and Treatment for advanced disease
Advances in gastric cancer: Biology and Treatment for advanced disease Andrés Cervantes Professor of Medicine Outline Molecular classification Pathology Classification after gene expression The Cancer
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationSystemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings
Systemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings Peter C. Enzinger, MD Dana-Farber Cancer Institute & Harvard Medical School 2017 Master Class Course
More informationGASTRIC CANCER TREATMENT REGIMENS (Part 1 of 6)
GASTRIC CANCER TREATMENT S (Part 1 of 6) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer
More informationMEETING SUMMARY ECC 2015, SEPTEMBER 25TH 29TH 2015 BY PROF. DR. HANS PRENEN, LEUVEN, BELGIUM. Cancers of the Upper GI Tract
Supported by an Independent Educa1onal Grant from MEETING SUMMARY ECC 2015, SEPTEMBER 25TH 29TH 2015 BY PROF. DR. HANS PRENEN, LEUVEN, BELGIUM Cancers of the Upper GI Tract RE-CLASSIFICATION OF GO CANCER
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationImmunotherapy for Upper GI Cancers
Immunotherapy for Upper GI Cancers Esophageal Adenocarcinoma GE Junction Adeno Gastric Carcinoma Ahmed Zakari MD Medical Director of GI Cancer Program, Florida Hospital Cancer Institute Associate Professor
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May
BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017
More informationManagement of advanced Gastric Cancer in the era of targeted therapy
Management of advanced Gastric Cancer in the era of targeted therapy Osman M.Mansour Prof. Medical Oncology, NCI, Cairo University BGO: 28-3 October 215 Gastric Cancer: A Significant Problem in Some Countries
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Priv. Doz. Dr. Dr. med. T.O. Götze Institute of Clinical Cancer Research Director: Prof. Dr. S.-E. Al- Batran University Cancer
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationRadiotherapy for Gastric Cancer. Nitin Ohri, M.D. Montefiore Medical Center Albert Einstein College of Medicine 12/15/2012
Radiotherapy for Gastric Cancer Nitin Ohri, M.D. Montefiore Medical Center Albert Einstein College of Medicine 12/15/2012 Disclosures I have no conflicts of interest to disclose. Outline Background Treatment
More informationTargeted Therapies in Gastric Cancer : Where Do We Stand Today. Yoon-Koo Kang Asan Medical Center, University of Ulsan Seoul, Korea
Targeted Therapies in Gastric Cancer : Where Do We Stand Today Yoon-Koo Kang Asan Medical Center, University of Ulsan Seoul, Korea Chemotherapy is the standard of care in advanced gastric cancer Median
More informationCa Cardias e Stomaco: le diversita e le terapie
XXII Riunione Nazionale I.T.M.O. Ca Cardias e Stomaco: le diversita e le terapie Maria Di Bartolomeo s.s. Oncologia Medica Gastroenterologica Fondazione IRCCS Istituto Nazionale Tumori Milano OUTLINE History
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More informationBIOLOGICAL TARGETED AGENTS
BIOLOGICAL TARGETED AGENTS (INCLUDING HER2, EGFR, ANGIOGENESIS) Dr Elizabeth Smyth Royal Marsden Hospital ESMO GI Cancer Preceptorship Singapore 2017 DISCLOSURES Honoraria for advisory role Five Prime
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationSystemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings
Systemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings Peter C. Enzinger, MD Dana-Farber Cancer Institute & Harvard Medical School 2018 Master Class Course
More informationFabienne Warmerdam Zuyderland
GE Fabienne Warmerdam Zuyderland Disclosure ASCO 2017 travelgrant Pfizer CRC ADJUVANT Less is more? More is More! 1 Less is more? Perspectief INT-0035 stadium III (niets vs 5-FU) 6.5-jaars OS 46% vs. 60%
More informationEsophageal Cancer. Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care. David Demos MD Thoracic Surgery Aurora Cancer Care
Esophageal Cancer Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care David Demos MD Thoracic Surgery Aurora Cancer Care No Disclosures Learning Objectives Review the classification scheme
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationGastric cancer and lung cancer impose a substantial
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non Small-Cell Lung Cancer By Loretta Fala, Medical Writer Gastric cancer and lung cancer impose a substantial
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More information